Psychedelic drugs including psilocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...
Clinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects. The present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms...
May 31, 2022Sanju Bala Dhull, Aarti Bains, Prince Chawla et al.2 citations
Mushrooms have been used in traditional medicine for centuries, although only relatively recently they have become a subject of intensive studies as a source of potential drugs and products that could be used in the treatment of many disorders. Mushroom-forming fungi are shown to produce a vast number of unique metabolites that exhibit various biological effects; these include polysaccharides,...
Mushrooms have been used in traditional medicine for centuries, although only relatively recently they have become a subject of intensive studies as a source of potential drugs and products that could be used in the treatment of many disorders. Mushroom-forming fungi are shown to produce a vast number of unique metabolites that exhibit various biological effects; these include polysaccharides,...
Background: Psychedelics represent a unique subset of psychoactive substances that can induce an aberrant state of consciousness principally via the neuronal 5-HT2A receptor. There is limited knowledge concerning the interest in these chemicals in Poland and how they changed during the pandemic. Nonetheless, these interests can be surveyed indirectly via the web. Objectives: We aim to conduct a...
Abstract Psilocybe magic mushrooms are best known for their main natural product, psilocybin, and its dephosphorylated congener, the psychedelic metabolite psilocin. Beyond tryptamines, the secondary metabolome of these fungi is poorly understood. The genomes of five species ( P. azurescens , P. cubensis , P. cyanescens , P. mexicana , and P. serbica ) were browsed to understand more profoundly...
International drug policy is rapidly evolving in tandem with promising evidence for psychedelic-assisted psychotherapy (PAP) in treating a range of mental health conditions. Canada is among the countries increasingly expanding access to psychedelic substances for therapeutic purposes. The 8-year ban on medical exemptions through the Canadian Special Access Programme was recently reversed in...
Langlitz and colleagues wrote about clinically used psychedelic drugs and the possibility of a “moral psychopharmacology” earlier in this journal (1). They emphasized the context-dependency of the effects of these substances (e.g., ayahuasca, psilocybin) and the importance of understanding their impact on social and moral cognition, particularly now that there is more research on their possible...
Depression has long been recognized as a major public health problem.Fear and anxiety associated with the high morbidity and mortality of COVID-19 have increased risk factors for mental health decline.A high prevalence of psychiatric disorders has been documented in individuals who have been directly or indirectly exposed to life-threatening situations.Current evidence suggests decompensation...
The active hallucinogen of magic mushrooms, psilocin, is being repurposed to treat nicotine addiction and treatment-resistant depression. Psilocin belongs to the tryptamine class of psychedelic compounds which include the hormone serotonin. It is believed that psilocin exerts its effect by binding to the serotonin 5-HT2A receptor. However, recent in-vivo evidence suggests that psilocin may...